Final results of the first phase I study of intraperitoneal administration of GL-ONC1, a marker gene modified vaccinia virus, in patients with peritoneal carcinomatosis
Keyword(s):
Phase I
◽
2018 ◽
Vol 24
(18)
◽
pp. 4388-4398
◽
2015 ◽
Vol 9
(suppl 1)
◽
pp. S39-S39
◽